Scotiabank Begins Coverage on Liquidia (NASDAQ:LQDA)

Scotiabank began coverage on shares of Liquidia (NASDAQ:LQDA) in a research note published on Wednesday, Marketbeat Ratings reports. The brokerage issued a sector outperform rating and a $30.00 price target on the stock.

Several other equities research analysts have also recently weighed in on the stock. Bank of America lowered their price target on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a research report on Tuesday, August 20th. Raymond James upgraded Liquidia from an “outperform” rating to a “strong-buy” rating in a report on Monday, August 19th. BTIG Research dropped their target price on Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a research report on Monday, August 19th. HC Wainwright reduced their price target on Liquidia from $32.00 to $29.00 and set a “buy” rating for the company in a research report on Tuesday, August 20th. Finally, Lifesci Capital began coverage on Liquidia in a research report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Liquidia currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.67.

Liquidia Stock Up 2.2 %

Shares of NASDAQ LQDA opened at $11.63 on Wednesday. Liquidia has a twelve month low of $5.71 and a twelve month high of $16.99. The firm has a market cap of $888.69 million, a PE ratio of -7.46 and a beta of 0.22. The business has a fifty day simple moving average of $10.42 and a two-hundred day simple moving average of $11.97.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. The firm had revenue of $3.66 million during the quarter, compared to the consensus estimate of $7.92 million. On average, research analysts expect that Liquidia will post -1.69 earnings per share for the current year.

Insider Transactions at Liquidia

In other Liquidia news, Director Caligan Partners Lp purchased 150,000 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was bought at an average cost of $9.51 per share, for a total transaction of $1,426,500.00. Following the completion of the purchase, the director now owns 6,994,997 shares in the company, valued at $66,522,421.47. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Caligan Partners Lp purchased 150,000 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was acquired at an average price of $9.51 per share, with a total value of $1,426,500.00. Following the completion of the acquisition, the director now owns 6,994,997 shares in the company, valued at approximately $66,522,421.47. This represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Roger Jeffs sold 8,053 shares of Liquidia stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $89,468.83. Following the sale, the chief executive officer now owns 812,193 shares of the company’s stock, valued at $9,023,464.23. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,731 shares of company stock valued at $249,571 in the last quarter. 31.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Patient Square Capital LP purchased a new stake in Liquidia in the first quarter valued at approximately $105,942,000. Farallon Capital Management LLC purchased a new position in Liquidia during the 1st quarter worth approximately $30,311,000. Sapient Capital LLC acquired a new stake in Liquidia during the 3rd quarter valued at approximately $1,336,000. BNP Paribas Financial Markets boosted its holdings in shares of Liquidia by 119.4% in the 1st quarter. BNP Paribas Financial Markets now owns 230,248 shares of the company’s stock valued at $3,396,000 after acquiring an additional 125,315 shares during the last quarter. Finally, HighVista Strategies LLC purchased a new stake in shares of Liquidia in the 2nd quarter valued at $1,461,000. 64.54% of the stock is owned by institutional investors and hedge funds.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).